VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Monday, August 14th. The company reported ($0.28) earnings per share for the quarter.
VistaGen Therapeutics, Inc. (NASDAQ VTGN) opened at $0.78 on Monday. VistaGen Therapeutics, Inc. has a fifty-two week low of $0.76 and a fifty-two week high of $4.12. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of -0.02.
COPYRIGHT VIOLATION WARNING: This report was originally published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://transcriptdaily.com/2017/11/06/vistagen-therapeutics-inc-vtgn-scheduled-to-post-quarterly-earnings-on-monday.html.
About VistaGen Therapeutics
VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).
Receive News & Ratings for VistaGen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.